We are pleased to announce that, as of June 1, 2024, Maurice Horsten will be joining our Supervisory Board.

Maurice brings a wealth of experience from his time at PharmaCell, a company specializing in regenerative medicine, where he was one of the investors and CEO. PharmaCell was successfully sold to Lonza SA.

He has also made significant contributions as the Director of the NV Bossche Investment Company (BIM), where he has developed extensive experience in managing public investment companies and establishing public-private partnerships like the Bossche Investment Fund (BIF).

In his current roles, Maurice serves on the supervisory boards of Brabant Life Sciences Seed Fund and Basic Pharma BV, among others. He has a proven track record in fostering collaboration between public, private, and academic institutions, which is crucial for advancing the regenerative medicine sector.

Bernard Mulder, General Director RegMed XB,

"We are very pleased to welcome Maurice to our Supervisory Board. His extensive experience and proven leadership in both the biotech industry and public-private partnerships will be invaluable as we continue to drive our mission forward."

We look forward to the significant contributions he will make to our organization.